CLINICAL TRIALS PROFILE FOR LARONIDASE
✉ Email this page to a colleague
All Clinical Trials for laronidase
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00144768 ↗ | A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients | Completed | BioMarin/Genzyme LLC | Phase 4 | 2004-07-01 | The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate. |
NCT00144768 ↗ | A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients | Completed | Genzyme, a Sanofi Company | Phase 4 | 2004-07-01 | The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate. |
NCT00176891 ↗ | Stem Cell Transplant w/Laronidase for Hurler | Completed | Masonic Cancer Center, University of Minnesota | Phase 2 | 2004-03-01 | The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for laronidase
Condition Name
Clinical Trial Locations for laronidase
Trials by Country
Clinical Trial Progress for laronidase
Clinical Trial Phase
Clinical Trial Sponsors for laronidase
Sponsor Name